Host mucin glycosylation plays a role in bacterial adhesion in lungs of individuals with cystic fibrosis. (October 2013)

• Record Type: Journal Article
• Authors: Venkatakrishnan, Vignesh; Packer, Nicolle H; Thaysen-Andersen, Morten
• Is Part Of: Expert review of respiratory medicine. Volume 7:Number 5(2013)
• Page Start: 553
• Page End: 576
• Publication Date: 2013-10
• Subjects: adhesion -- cystic fibrosis -- glycan -- glycosidase -- infection -- inflammation -- lectin -- lung -- mucin -- mucous -- Pseudomonas aeruginosa -- protein glycosylation -- respiratory system -- sputum; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Treatment -- Periodicals; 616.2005
• DOI: 10.1586/17476348.2013.837752
• Languages: English
• ISSNs: 1747-6348

Abstract

Malfunction of the cell surface glycoprotein, cystic fibrosis transmembrane conductance regulator, is the molecular hallmark of cystic fibrosis (CF), causing salt imbalance across the lung epithelium and biochemical and biophysical alterations of the mucous secretion and airway surfaces. Abnormal glycosylation of both secreted and membrane-tethered airway mucins in CF hosts are reported by a substantial body of literature and correlates with bacterial infection and inflammation in CF airways, features that are linked to the CF pathology. It is established that Pseudomonas aeruginosa and other CF-typic bacteria use the altered host mucin glycosylation as receptors for adhesion by dedicated lectins and adhesins recognizing an array of the aberrantly expressed glycan determinants. This review aims to describe the aberrant mucin glycosylation phenotype observed in CF airways relative to the non-CF equivalent by summarizing the wealth of literature on this topic. The possible causes and effects of altered glycosylation in the respiratory system are discussed. Specific attention is given to the adhesion mechanisms of the opportunistic P. aeruginosa, which utilizes the molecular alterations of the lung to gain access to the normally sterile airways. Finally, the emerging glycosylation-based therapeutics that show promising potential for reducing bacterial infection in individuals with CF by molecular mimicry mechanisms are discussed.